vs

Side-by-side financial comparison of Clorox (CLX) and Leonardo DRS, Inc. (DRS). Click either name above to swap in a different company.

Clorox is the larger business by last-quarter revenue ($1.7B vs $1.1B, roughly 1.6× Leonardo DRS, Inc.). Leonardo DRS, Inc. runs the higher net margin — 9.6% vs 9.4%, a 0.2% gap on every dollar of revenue. On growth, Leonardo DRS, Inc. posted the faster year-over-year revenue change (8.1% vs 0.3%). Over the past eight quarters, Leonardo DRS, Inc.'s revenue compounded faster (24.1% CAGR vs -8.3%).

The Clorox Company is an American multinational manufacturer and marketer of consumer and professional products. Clorox ranked annually on the Fortune 500 list from 2000 to 2024, where it last held the #485 spot.

Leonardo DRS, Inc. is a United States–based defense contractor. Originally founded as DRS Technologies, Inc. and traded on the NYSE, it was acquired by Leonardo’s predecessor Finmeccanica in 2008. Leonardo DRS provides advanced defense technologies and systems primarily to the U.S. military.

CLX vs DRS — Head-to-Head

Bigger by revenue
CLX
CLX
1.6× larger
CLX
$1.7B
$1.1B
DRS
Growing faster (revenue YoY)
DRS
DRS
+7.8% gap
DRS
8.1%
0.3%
CLX
Higher net margin
DRS
DRS
0.2% more per $
DRS
9.6%
9.4%
CLX
Faster 2-yr revenue CAGR
DRS
DRS
Annualised
DRS
24.1%
-8.3%
CLX

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
CLX
CLX
DRS
DRS
Revenue
$1.7B
$1.1B
Net Profit
$157.0M
$102.0M
Gross Margin
43.2%
25.4%
Operating Margin
11.9%
Net Margin
9.4%
9.6%
Revenue YoY
0.3%
8.1%
Net Profit YoY
-15.6%
14.6%
EPS (diluted)
$1.29
$0.38

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLX
CLX
DRS
DRS
Q4 25
$1.7B
$1.1B
Q3 25
$960.0M
Q2 25
$2.0B
$829.0M
Q1 25
$1.7B
$799.0M
Q4 24
$1.7B
$981.0M
Q3 24
$1.8B
$812.0M
Q2 24
$1.9B
$753.0M
Q1 24
$1.8B
$688.0M
Net Profit
CLX
CLX
DRS
DRS
Q4 25
$157.0M
$102.0M
Q3 25
$72.0M
Q2 25
$332.0M
$54.0M
Q1 25
$186.0M
$50.0M
Q4 24
$193.0M
$89.0M
Q3 24
$99.0M
$57.0M
Q2 24
$216.0M
$38.0M
Q1 24
$-51.0M
$29.0M
Gross Margin
CLX
CLX
DRS
DRS
Q4 25
43.2%
25.4%
Q3 25
23.1%
Q2 25
46.5%
23.8%
Q1 25
44.6%
22.7%
Q4 24
43.8%
24.0%
Q3 24
45.8%
22.0%
Q2 24
46.5%
22.4%
Q1 24
42.2%
22.2%
Operating Margin
CLX
CLX
DRS
DRS
Q4 25
11.9%
Q3 25
9.7%
Q2 25
20.6%
8.4%
Q1 25
15.2%
7.4%
Q4 24
14.1%
12.2%
Q3 24
10.0%
9.2%
Q2 24
14.5%
7.3%
Q1 24
-2.3%
6.3%
Net Margin
CLX
CLX
DRS
DRS
Q4 25
9.4%
9.6%
Q3 25
7.5%
Q2 25
16.7%
6.5%
Q1 25
11.2%
6.3%
Q4 24
11.4%
9.1%
Q3 24
5.6%
7.0%
Q2 24
11.4%
5.0%
Q1 24
-2.8%
4.2%
EPS (diluted)
CLX
CLX
DRS
DRS
Q4 25
$1.29
$0.38
Q3 25
$0.26
Q2 25
$2.68
$0.20
Q1 25
$1.50
$0.19
Q4 24
$1.54
$0.34
Q3 24
$0.80
$0.21
Q2 24
$1.74
$0.14
Q1 24
$-0.41
$0.11

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLX
CLX
DRS
DRS
Cash + ST InvestmentsLiquidity on hand
$227.0M
$647.0M
Total DebtLower is stronger
$321.0M
Stockholders' EquityBook value
$-125.0M
$2.7B
Total Assets
$5.6B
$4.5B
Debt / EquityLower = less leverage
0.12×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLX
CLX
DRS
DRS
Q4 25
$227.0M
$647.0M
Q3 25
$309.0M
Q2 25
$167.0M
$278.0M
Q1 25
$226.0M
$380.0M
Q4 24
$290.0M
$598.0M
Q3 24
$278.0M
$198.0M
Q2 24
$202.0M
$149.0M
Q1 24
$219.0M
$160.0M
Total Debt
CLX
CLX
DRS
DRS
Q4 25
$321.0M
Q3 25
$326.0M
Q2 25
$2.5B
$331.0M
Q1 25
$335.0M
Q4 24
$340.0M
Q3 24
$345.0M
Q2 24
$2.5B
$351.0M
Q1 24
$356.0M
Stockholders' Equity
CLX
CLX
DRS
DRS
Q4 25
$-125.0M
$2.7B
Q3 25
$2.6B
Q2 25
$321.0M
$2.6B
Q1 25
$27.0M
$2.6B
Q4 24
$-41.0M
$2.6B
Q3 24
$60.0M
$2.5B
Q2 24
$328.0M
$2.4B
Q1 24
$91.0M
$2.4B
Total Assets
CLX
CLX
DRS
DRS
Q4 25
$5.6B
$4.5B
Q3 25
$4.2B
Q2 25
$5.6B
$4.1B
Q1 25
$5.5B
$4.1B
Q4 24
$5.6B
$4.2B
Q3 24
$5.5B
$3.9B
Q2 24
$5.8B
$3.8B
Q1 24
$5.8B
$3.8B
Debt / Equity
CLX
CLX
DRS
DRS
Q4 25
0.12×
Q3 25
0.12×
Q2 25
7.74×
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.14×
Q2 24
7.56×
0.15×
Q1 24
0.15×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLX
CLX
DRS
DRS
Operating Cash FlowLast quarter
$425.0M
Free Cash FlowOCF − Capex
$376.0M
FCF MarginFCF / Revenue
35.5%
Capex IntensityCapex / Revenue
4.6%
Cash ConversionOCF / Net Profit
4.17×
TTM Free Cash FlowTrailing 4 quarters
$227.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLX
CLX
DRS
DRS
Q4 25
$425.0M
Q3 25
$107.0M
Q2 25
$294.0M
$-28.0M
Q1 25
$286.0M
$-138.0M
Q4 24
$180.0M
$443.0M
Q3 24
$221.0M
$59.0M
Q2 24
$340.0M
$34.0M
Q1 24
$182.0M
$-265.0M
Free Cash Flow
CLX
CLX
DRS
DRS
Q4 25
$376.0M
Q3 25
$77.0M
Q2 25
$219.0M
$-56.0M
Q1 25
$233.0M
$-170.0M
Q4 24
$127.0M
$414.0M
Q3 24
$182.0M
$47.0M
Q2 24
$259.0M
$0
Q1 24
$127.0M
$-275.0M
FCF Margin
CLX
CLX
DRS
DRS
Q4 25
35.5%
Q3 25
8.0%
Q2 25
11.0%
-6.8%
Q1 25
14.0%
-21.3%
Q4 24
7.5%
42.2%
Q3 24
10.3%
5.8%
Q2 24
13.6%
0.0%
Q1 24
7.0%
-40.0%
Capex Intensity
CLX
CLX
DRS
DRS
Q4 25
4.6%
Q3 25
3.1%
Q2 25
3.8%
3.4%
Q1 25
3.2%
4.0%
Q4 24
3.1%
3.0%
Q3 24
2.2%
1.5%
Q2 24
4.3%
4.5%
Q1 24
3.0%
1.5%
Cash Conversion
CLX
CLX
DRS
DRS
Q4 25
4.17×
Q3 25
1.49×
Q2 25
0.89×
-0.52×
Q1 25
1.54×
-2.76×
Q4 24
0.93×
4.98×
Q3 24
2.23×
1.04×
Q2 24
1.57×
0.89×
Q1 24
-9.14×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CLX
CLX

Health And Wellness$643.0M38%
Household$419.0M25%
Lifestyle$321.0M19%
Other$290.0M17%

DRS
DRS

Segment breakdown not available.

Related Comparisons